Watching obesity on a new channel

Researchers at the University of California, Irvine, have found a potassium channel Kv1.3 inhibitor that may help treat obesity-related diseases.¹ The team had previously licensed one inhibitor, ShK-186, to Kineta Inc. for autoimmune indications-the biotech is now planning to test it also in obesity or metabolic syndrome.

Potassium channel Kv1.3 (KCNA3) has long been associated with immune regulation owing to its expression on effector-memory ...